MX2021003655A - Derivado de indol macrociclico, metodo de preparacion del mismo y aplicacion del mismo en medicina. - Google Patents
Derivado de indol macrociclico, metodo de preparacion del mismo y aplicacion del mismo en medicina.Info
- Publication number
- MX2021003655A MX2021003655A MX2021003655A MX2021003655A MX2021003655A MX 2021003655 A MX2021003655 A MX 2021003655A MX 2021003655 A MX2021003655 A MX 2021003655A MX 2021003655 A MX2021003655 A MX 2021003655A MX 2021003655 A MX2021003655 A MX 2021003655A
- Authority
- MX
- Mexico
- Prior art keywords
- preparation
- method therefor
- medicine
- application
- indole
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se refiere a un derivado de indol macrocíclico, un método de preparación del mismo y una aplicación del mismo en medicina. Específicamente, la presente invención se refiere a un derivado de indol macrocíclico representado por la fórmula general (IM), un método de preparación del mismo, una composición farmacéutica que contiene el derivado y un uso del mismo como un agente terapéutico, especialmente como un inhibidor de MCL-1. Cada sustituyente de la fórmula general (IM) es el mismo que los definidos en la descripción. (ver Fórmula).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811156217 | 2018-09-30 | ||
| CN201910227359 | 2019-03-25 | ||
| PCT/CN2019/108322 WO2020063792A1 (zh) | 2018-09-30 | 2019-09-27 | 吲哚类大环衍生物、其制备方法及其在医药上的应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021003655A true MX2021003655A (es) | 2021-06-23 |
Family
ID=69953395
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021003655A MX2021003655A (es) | 2018-09-30 | 2019-09-27 | Derivado de indol macrociclico, metodo de preparacion del mismo y aplicacion del mismo en medicina. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220041623A1 (es) |
| EP (1) | EP3858840A4 (es) |
| JP (1) | JP2022503896A (es) |
| KR (1) | KR20210070312A (es) |
| CN (1) | CN112533929B (es) |
| AU (1) | AU2019347963A1 (es) |
| BR (1) | BR112021004805A2 (es) |
| CA (1) | CA3113917A1 (es) |
| MX (1) | MX2021003655A (es) |
| TW (1) | TW202014423A (es) |
| WO (1) | WO2020063792A1 (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110845520B (zh) | 2018-11-22 | 2021-04-13 | 苏州亚盛药业有限公司 | 作为mcl-1抑制剂的大环吲哚 |
| MA56505A (fr) * | 2019-06-21 | 2022-04-27 | Janssen Pharmaceutica Nv | Inhibiteurs macrocycliques de mcl-1 |
| MX2022006180A (es) | 2019-11-21 | 2022-06-14 | Janssen Pharmaceutica Nv | Derivados macrociclicos de sulfonilo como inhibidores de mcl-1. |
| US20230021562A1 (en) | 2019-11-21 | 2023-01-26 | Janssen Pharmaceutica Nv | Macrocylic indole derivatives mcl-1 inhibitors |
| CN115052880A (zh) * | 2019-12-18 | 2022-09-13 | 芝诺管理公司 | 大环化合物 |
| KR20220143906A (ko) * | 2020-02-21 | 2022-10-25 | 얀센 파마슈티카 엔.브이. | Mcl-1의 억제제로서의 거대환식 인돌 유도체 |
| WO2021197295A1 (zh) * | 2020-03-30 | 2021-10-07 | 江苏恒瑞医药股份有限公司 | 一种吲哚类大环衍生物的结晶形式及其制备方法 |
| WO2021239862A1 (en) | 2020-05-29 | 2021-12-02 | Janssen Pharmaceutica Nv | Macrocyclic 7-pyrazol-5-yl-indole derivatives as inhibitors of mcl-1 |
| MX2022016004A (es) | 2020-06-19 | 2023-04-11 | Janssen Pharmaceutica Nv | Desderivados de 7-(pirazol-5-il)-indol macrociclicos enlazados a n como inhibidores de mcl-1. |
| CA3181816A1 (en) | 2020-06-19 | 2021-12-23 | Aldo Peschiulli | N-linked macrocyclic 4-(pyrazol-5-yl)-indole derivatives as inhibitors of mcl-1 |
| JP2023532592A (ja) | 2020-07-08 | 2023-07-28 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｍｃｌ－１の阻害剤としての大環状エーテル含有インドール誘導体 |
| AU2021403616A1 (en) | 2020-12-17 | 2023-08-03 | Janssen Pharmaceutica Nv | Branched macrocyclic 4-(pyrazol-5-yl)-indole derivatives as inhibitors of mcl-1 |
| CA3206202A1 (en) | 2021-02-12 | 2022-08-18 | Janssen Pharmaceutica Nv | Macrocyclic 1,3-bridged 6-chloro-7-pyrazol-4-yl-1h-indole-2-carboxylate and 6-chloro-7-pyrimidin-5-yl-1h-indole-2-carboxylate derivatives as mcl-1 inhibitors for the treatment of cancer |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2134685E (pt) * | 2007-04-16 | 2015-11-25 | Abbvie Inc | Derivados de índole não substituídos na posição 7 como inibidores de mcl-1 |
| BRPI0810365A2 (pt) * | 2007-04-16 | 2014-10-29 | Abbott Lab | Inibidores de mlc-1 de indol 7-substituído |
| WO2017156181A1 (en) | 2016-03-09 | 2017-09-14 | Raze Therapeutics, Inc. | 3-phosphoglycerate dehydrogenase inhibitors and uses thereof |
| PT3445767T (pt) | 2016-04-22 | 2020-05-13 | Astrazeneca Ab | Inibidores de mcl-1 macrocíclicos para o tratamento de cancro |
| TW201904976A (zh) * | 2017-03-31 | 2019-02-01 | 瑞典商阿斯特捷利康公司 | Ｍｃｌ-１抑制劑及其使用方法 |
| CN110845520B (zh) * | 2018-11-22 | 2021-04-13 | 苏州亚盛药业有限公司 | 作为mcl-1抑制剂的大环吲哚 |
| MA56505A (fr) * | 2019-06-21 | 2022-04-27 | Janssen Pharmaceutica Nv | Inhibiteurs macrocycliques de mcl-1 |
-
2019
- 2019-09-27 EP EP19864112.8A patent/EP3858840A4/en not_active Withdrawn
- 2019-09-27 BR BR112021004805-7A patent/BR112021004805A2/pt not_active Application Discontinuation
- 2019-09-27 TW TW108135199A patent/TW202014423A/zh unknown
- 2019-09-27 AU AU2019347963A patent/AU2019347963A1/en not_active Abandoned
- 2019-09-27 MX MX2021003655A patent/MX2021003655A/es unknown
- 2019-09-27 WO PCT/CN2019/108322 patent/WO2020063792A1/zh active Application Filing
- 2019-09-27 CA CA3113917A patent/CA3113917A1/en active Pending
- 2019-09-27 CN CN201980049788.6A patent/CN112533929B/zh active Active
- 2019-09-27 JP JP2021517593A patent/JP2022503896A/ja active Pending
- 2019-09-27 US US17/281,525 patent/US20220041623A1/en active Pending
- 2019-09-27 KR KR1020217011755A patent/KR20210070312A/ko unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20210070312A (ko) | 2021-06-14 |
| CN112533929B (zh) | 2022-09-16 |
| CA3113917A1 (en) | 2020-04-02 |
| US20220041623A1 (en) | 2022-02-10 |
| EP3858840A4 (en) | 2022-05-04 |
| JP2022503896A (ja) | 2022-01-12 |
| CN112533929A (zh) | 2021-03-19 |
| EP3858840A1 (en) | 2021-08-04 |
| TW202014423A (zh) | 2020-04-16 |
| BR112021004805A2 (pt) | 2021-06-01 |
| AU2019347963A1 (en) | 2021-05-27 |
| WO2020063792A1 (zh) | 2020-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021003655A (es) | Derivado de indol macrociclico, metodo de preparacion del mismo y aplicacion del mismo en medicina. | |
| MX2019005379A (es) | Derivado de pirazolo-heteroarilo, metodo de preparacion y uso medico del mismo. | |
| MX2021006026A (es) | Pirimidina y derivado heterociclico de nitrogeno de cinco miembros, metodo de preparacion y usos medicos de los mismos. | |
| MX2019003143A (es) | Compuesto heterociclico sustituido con alquinilo, su metodo de preparacion y su uso medico. | |
| PH12020551305A1 (en) | Pharmaceutical Compounds | |
| MY196909A (en) | Boronic acid derivatives and therapeutic uses thereof | |
| MX368504B (es) | Derivados de amidas y sales farmaceuticamente aceptables de los mismos, método de preparación de los mismos y aplicación médica de los mismos. | |
| PH12018500904A1 (en) | Peptide macrocycles against acinetobacter baumannii | |
| MX2019001481A (es) | Derivado de oxopicolinamida, metodo de preparacion y uso farmaceutico del mismo. | |
| MY195194A (en) | Substituted Indoline Derivatives as Dengue Viral Replication Inhibitors | |
| MX2020013785A (es) | Derivado de la pirido-pirimidina, metodo de preparacion del mismo y uso medico del mismo. | |
| SA519402103B1 (ar) | 1,6-naphthyridine مشتقات 1، 6 نفثيرايدين CDK4/6 على شكل مثبط | |
| MX2021011823A (es) | Derivado pirroloheterociclico, metodo de preparacion del mismo y su aplicacion en medicina. | |
| MX2020011818A (es) | Derivados de piridincarboxamida, su metodo de preparacion y sus usos farmaceuticos. | |
| AU2017269673A1 (en) | Pyridine dicarboxamide derivatives as bromodomain inhibitors | |
| MX2021006866A (es) | Benzamidas de derivados de pirazolil-amino-pirimidinilo y composiciones y métodos de las mismas. | |
| AU2020288567A8 (en) | Pyrrolopyrimidine compound and use thereof | |
| MX2017000183A (es) | Amidas de benzoxazinona como moduladores del receptor de mineralocorticoides. | |
| PH12021551057A1 (en) | Macrocyclic tyrosine kinase inhibitor and uses thereof | |
| MX2022001789A (es) | Derivados de 2-hidroxicicloalcan-1-carbamoilo. | |
| ZA202206481B (en) | Amide derivative and preparation method therefore and use thereof in medicine | |
| SA519410865B1 (ar) | مركب حلقي شبيه بكُومارين بوصفه مثبط mek واستخدامه | |
| NZ764004A (en) | Heteroaryl compounds as muscarinic m1 receptor positive allosteric modulators | |
| PH12018501563A1 (en) | Indane derivatives as mglur7 modulators | |
| MX2019007360A (es) | Derivado de triazol azabiciclo-sustituido, preparacion, metodo del mismo, y aplicacion de la misma en medicina. |